Evidence map›Paper›PMID 36658621›Full record

ArticleClinical epigenetics2023

Hypomethylation in MTNR1B: a novel epigenetic marker for atherosclerosis profiling using stenosis radiophenotype and blood inflammatory cells.

Jee Yeon Kim, Jaroslav Jelinek, Young Ho Lee, Dae Hyun Kim, Keunsoo Kang, Su Hyun Ryu, Hye Rin Moon, Kwangjo Cho, Seo Hee Rha, Jae Kwan Cha and 2 more

Open access · goldAbstract read
In one paragraph

Article in Clinical epigenetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Clinical value of LncRNA PAX8-AS1 as a biomarker for sepsis diagnosis and prognosis and its regulatory mechanism via the miR-34a-5p/HDAC1 axis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  2. Promoter hypomethylation ofFrontiers in genetics · 2026
    Article
  3. Article
  4. Research progress of stem cells in the treatment of atherosclerosis.Frontiers in cell and developmental biology · 2025
    Review
  5. Article
  6. Article
  7. Myocardial Infarction Susceptibility and theInternational journal of molecular sciences · 2023
    Article
  8. Melatonin: A Potential Regulator of DNA Methylation.Antioxidants (Basel, Switzerland) · 2023
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Jee Yeon KimDepartment of Neurology and Neuroepigenetics Laboratory, College of Medicine and Hospital, Chungnam National University, 282 Moonhwaro, Joongku, Daejeon, 35015, South Korea.
Jaroslav JelinekCoriell Institute for Medical Research, Camden, NJ, USA.
Young Ho LeeDepartment of Anatomy, College of Medicine, Chungnam National University, Daejeon, South Korea.
Dae Hyun KimDepartment of Neurology, Dong-A University Hospital, Busan, South Korea.
Keunsoo KangDepartment of Microbiology, College of Science and Technology, Dankook University, Cheonan, South Korea.
Su Hyun RyuDepartment of Neurology and Neuroepigenetics Laboratory, College of Medicine and Hospital, Chungnam National University, 282 Moonhwaro, Joongku, Daejeon, 35015, South Korea.
Hye Rin MoonDepartment of Neurology and Neuroepigenetics Laboratory, College of Medicine and Hospital, Chungnam National University, 282 Moonhwaro, Joongku, Daejeon, 35015, South Korea.
Kwangjo ChoDepartment of Thoracic and Cardiovascular Surgery, Dong-A University Hospital, Busan, South Korea.
Seo Hee RhaDepartment of Pathology, Dong-A University Hospital, Busan, South Korea.
Jae Kwan ChaDepartment of Anatomy, College of Medicine, Chungnam National University, Daejeon, South Korea.
Jean-Pierre J IssaCoriell Institute for Medical Research, Camden, NJ, USA.
Jei KimDepartment of Neurology and Neuroepigenetics Laboratory, College of Medicine and Hospital, Chungnam National University, 282 Moonhwaro, Joongku, Daejeon, 35015, South Korea. jeikim@cnu.ac.kr.
Chungnam National University · KRDong-A University Hospital · KRCoriell Institute For Medical Research · USChungnam National University Hospital · KRDankook University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChanges in gene-specific promoter methylation may result from aging and environmental influences. Atherosclerosis is associated with aging and environmental effects. Thus, promoter methylation profiling may be used as an epigenetic tool to evaluate the impact of aging and the environment on atherosclerosis development. However, gene-specific methylation changes are currently inadequate epigenetic markers for predicting atherosclerosis and cardiovascular disease pathogenesis.

resultsWe profiled and validated changes in gene-specific promoter methylation associated with atherosclerosis using stenosis radiophenotypes of cranial vessels and blood inflammatory cells rather than direct sampling of atherosclerotic plaques. First, we profiled gene-specific promoter methylation changes using digital restriction enzyme analysis of methylation (DREAM) sequencing in peripheral blood mononuclear cells from eight samples each of cranial vessels with and without severe-stenosis radiophenotypes. Using DREAM sequencing profiling, 11 tags were detected in the promoter regions of the ACVR1C, ADCK5, EFNA2, ENOSF1, GLS2, KNDC1, MTNR1B, PACSIN3, PAX8-AS1, TLDC1, and ZNF7 genes. Using methylation evaluation, we found that EFNA2, ENOSF1, GLS2, KNDC1, MTNR1B, PAX8-AS1, and TLDC1 showed > 5% promoter methylation in non-plaque intima, atherosclerotic vascular tissues, and buffy coats. Using logistic regression analysis, we identified hypomethylation of MTNR1B as an independent variable for the stenosis radiophenotype prediction model by combining it with traditional atherosclerosis risk factors including age, hypertension history, and increases in creatinine, lipoprotein (a), and homocysteine. We performed fivefold cross-validation of the prediction model using 384 patients with ischemic stroke (50 [13%] no-stenosis and 334 [87%] > 1 stenosis radiophenotype). For the cross-validation, the training dataset included 70% of the dataset. The prediction model showed an accuracy of 0.887, specificity to predict stenosis radiophenotype of 0.940, sensitivity to predict no-stenosis radiophenotype of 0.533, and area under receiver operating characteristic curve of 0.877 to predict stenosis radiophenotype from the test dataset including 30% of the dataset.

conclusionsWe identified and validated MTNR1B hypomethylation as an epigenetic marker to predict cranial vessel atherosclerosis using stenosis radiophenotypes and blood inflammatory cells rather than direct atherosclerotic plaque sampling.

Indexed as

AtherosclerosisPlaque, AtheroscleroticActivin Receptors, Type IDNA MethylationEpigenesis, GeneticHumansLeukocytes, MononuclearReceptor, Melatonin, MT2Activin Receptors, Type IACVR1C protein, humanMTNR1B protein, humanReceptor, Melatonin, MT2AtherosclerosisBlood inflammatory cellsPromoter methylation profilingRadioepigenomicsStenosis radiophenotype

Identifiers

PMID36658621
PMCPMC9854223
OpenAlexW4317500324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.